Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Virus-Inspired modular Assembly for cargo loading in Extracellular Vesicles-Inspired CArdiac REpair

Project description

Drug delivery with virus-inspired nanotech

Traditional drug delivery methods often struggle with precision and efficiency, leading to limited therapeutic impact and side effects. Extracellular vesicles (EVs) are natural nanosized carriers between cells. They hold promise but face challenges in targeted loading and release. In this context, the ERC-funded VIA-EVICARE project is testing the feasibility of a virus-inspired, modular EV technology. By engineering self-assembling viral proteins and integrating them into EV production, the project aims to boost delivery precision, scalability, and cost-effectiveness. Alongside technical validation, VIA-EVICARE is mapping the IP landscape and preparing a business strategy to bring this breakthrough platform closer to real-world treatments for a range of diseases.

Objective

The fundamental objective of the VIA-EVICARE ERC Proof of Concept project is to ascertain the technical and commercial feasibility of a ground-breaking technology to revolutionize the delivery of therapeutics via extracellular vesicles (EVs). EVs are naturally occurring nanosized vesicles that facilitate the transfer of biological cargo between cells and offer numerous benefits over conventional drug delivery systems. By leveraging a novel, virus-inspired mechanism, we aim for a modular design that combines a significant improvement of targeting, loading, and release of therapeutics that overcomes the limitations of existing strategies. By designing and synthesizing self-assembling viral proteins and recruiting EV biogenesis components, we aim to:
I. Validating the efficiency and specificity of EV-therapeutic loading, EV-generation, and EV uptake mechanisms upon introduction of different self-assembling proteins.
II. Optimizing the modular design for large-scale production, ensuring reproducibility and cost-effectiveness and validate our innovative VIA-EVICARE loading strategy by assessing biodistribution and functional delivery in vivo.
III. Conduct a comprehensive intellectual property (IP) landscape analysis to establish freedom-to-operate (FTO) and ensure that our technology can be commercialized without infringing on existing patents.
IV. Develop a robust and detailed business plan to effectively guide the commercialization of our loading technology, thus bringing a transformative solution to treating various diseases.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Net EU contribution
€ 150 000,00
Address
HEIDELBERGLAAN 100
3584 CX Utrecht
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)